Co-administration of anti-PD-1 molecules increases the efficacy of DCs-based vaccines, in terms of enforced intratumoral CD8+ T cell responses and trafficking of CD8+ memory T cells, as observed in a preclinical model of glioblastoma (177). Here, CD8A is linked to glioblastoma.